<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922465</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-109</org_study_id>
    <nct_id>NCT02922465</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effects of clopidogrel on the PK of
      K-877 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma exposure of K-877 by measuring Cmax when administered alone or with Clopidogrel</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma exposure of K-877 by measuring AUC when administered alone or with Clopidogrel</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of 20 participants with treatment emergent adverse events as assessed by the principle investigator</measure>
    <time_frame>Through study completion up to 17 days.</time_frame>
    <description>Subjects will be questioned in a general way by the investigator without specific symptoms suggested.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>K-877 &amp; Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 &amp; Clopidogrel orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877</intervention_name>
    <arm_group_label>K-877 &amp; Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>K-877 &amp; Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject provides written informed consent before any study-specific evaluation is
             performed;

          -  Subject is a healthy adult male or female volunteer between the ages of 18 and 45
             years, inclusive at screening;

          -  Subject has a BMI of 18 to 30 kg/mÂ², inclusive;

          -  Subject has hematology, serum chemistry, and urinalysis test results within the
             reference ranges, or results that do not show clinically significant abnormalities, as
             judged by the Investigator at screening and check-in;

        Exclusion Criteria:

          -  Subject is a woman who is pregnant or breastfeeding;

          -  Subject has clinically significant abnormalities in the screening or check-in
             assessments;

          -  Subject has current or history of clinically significant coagulation, bleeding, or
             platelet disorders;

          -  Subject or a family member of the subject has a history of coagulation or bleeding
             disorders or reasonable suspicion of vascular malformations, including aneurysms;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

